Whitehawk Therapeutics Presents Comprehensive Preclinical Data Highlighting its Next-Generation ADC Portfolio at the AACR 2026 [TheStreet.com]
Whitehawk Therapeutics, Inc. (WHWK)
Company Research
Source: TheStreet.com
PR Newswire MORRISTOWN, N.J., April 19, 2026 Data demonstrate preclinical proof-of-concept for HWK-007, HWK-016 and HWK-206, underpinned by Whitehawk's proprietary Carbon Bridge Cysteine Re-pairing platform Tumor regressions observed across various cancer models at low single - digit mg/kg doses, with favorable tolerability (HNSTD 60 mg/kg) and low systemic levels of free payload (=0.01% AUC) Phase 1 trials for HWK-007 and HWK-016 are ongoing; an IND submission for HWK-206 is on track for mid-2026 MORRISTOWN, N.J. April 19, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced the presentation of new preclinical data across its ADC portfolio at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place April 17-22, 2026, in San Diego,
Show less
Read more
Impact Snapshot
Event Time:
WHWK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
WHWK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
WHWK alerts
High impacting Whitehawk Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
WHWK
News
- Whitehawk Therapeutics Presents Comprehensive Preclinical Data Highlighting its Next-Generation ADC Portfolio at the AACR 2026 [Yahoo! Finance]Yahoo! Finance
- Whitehawk Therapeutics Presents Comprehensive Preclinical Data Highlighting its Next-Generation ADC Portfolio at the AACR 2026PR Newswire
- Whitehawk Therapeutics to Participate in Jones Trading Post-AACR Fireside Chat Series [TheStreet.com]TheStreet.com
- Whitehawk Therapeutics to Participate in Jones Trading Post-AACR Fireside Chat SeriesPR Newswire
- Whitehawk Therapeutics (WHWK) is now covered by Citizens Jmp. They set a "market outperform" rating and a $8.00 price target on the stock.MarketBeat
WHWK
Earnings
- 3/12/26 - Beat
WHWK
Sec Filings
- 4/17/26 - Form 4
- 4/15/26 - Form 144
- 4/15/26 - Form 4
- WHWK's page on the SEC website